Starting the week of September 22, Ontario residents aged 60 to 74 who meet certain high-risk criteria or live in specific ...

Ontario announced today its schedule for the fall immunization programs, encouraging residents to get flu and COVID-19 ...

L1, Keytruda, approaches loss of exclusivity (LOE) in 2028. The drug is the company's biggest revenue driver, accounting for ...

Respiratory illnesses in the region have been delayed by warm September weather, says Niagara Health’s infectious disease ...

GSK plc GSK is one of the key vaccine makers in the world, marketing vaccines to help prevent infectious diseases like ...

Toronto — Ontario is rolling out an expanded fall immunization campaign aimed at protecting residents from a seasonal surge ...

Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.

Two new real-world studies estimate the effectiveness of a single dose of a respiratory syncytial virus (RSV) vaccine against ...

Pfizer and Bristol Myers Squibb are trading for less than $50 per share. Despite patent cliffs and other issues they face, both could rebound. Both have strong dividend programs and look attractive at ...

每年秋冬，气温转凉，呼吸道合胞病毒（RSV）便开始肆虐，成为人们健康的一大威胁。尤其是婴幼儿、老年人以及免疫力低下者，一旦感染 RSV，可能引发如毛细支气管炎、肺炎等严重疾病，甚至危及生命。据相关数据显示，在婴幼儿呼吸道感染病例中，RSV 感染占比居高不下，是导致婴幼儿因下呼吸道感染住院的首要病因 。对于 60 岁以上的老年人，感染 RSV 后住院风险和重症风险也显著增加 。 不过现在有个好消息！

Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition ...